You are here:HOME>Products>Diagnostic Reagents>COVID-19 Human IgM/IgG Rapid Test(EIA)
Contact Us:

COVID-19 Human IgM/IgG Rapid Test(EIA)

  • Code:
  • Grade:
  • Package:
  • Function:
  • Application:

    Intended Use

    This product is a lateral flow immunoassay for the rapid detection of human IgM and IgG antibodies against COVID-19 virus in human whole blood, plasma, or serum. This product is for professional use only.


    In 2019, a novel coronavirus was identified as the cause of an outbreak of severe respiratory disease in China. On February 11, 2020, the disease was officially named “Coronavirus Disease 2019” (COVID19). As the first line of defense against viral infection, human IgM antibody is generated when one becomes infected with the COVID-19 virus. The level of IgM will rise within 2 weeks and then drop; accordingly, a second antibody IgG, which is more protective than IgM antibody, develops within 4 weeks. Therefore, the detection of human IgM/IgG antibodies in blood not only serves as an evidence of viral exposure, but also provides the stage of infection and antibody protection.


    COVID-19 Human IgM/IgG Rapid Test utilizes the technique of chromatography and qualitative immunoassay to detect the presence of IgM and IgG antibodies against COVID-19 virus in human whole blood, plasma or serum. During testing, the blood sample firstly interacts with COVID-19 protein antigen labeled gold nanoparticles in the sample zone. By capillary action, the mixed sample flows across the membrane strip. Human IgM antibodies interact with the antihuman IgM antibody coated in the IgM result zone showing a visible colored line. Similarly, a colored line in the IgG test zone demonstrates the presence of human IgG antibodies. Control line must appear every time to ensure the quality of the sample processing.

Customers Also Viewed